Contact Us

Recombinant Overlapping Peptides

Home
Blog Standard
Tag: Recombinant Overlapping Peptides
Sarah Cannon Research Institute
Company News
February 20, 2025 Oxford Vacmedix Comments: 0

First patient treated with new extended dosing of OVM-200 cancer vaccine

Extended dosing of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been approved by the MHRA for use in the ongoing Phase 1 clinical trial Oxford, UK – 20th February 2025 Press Release: First patient treated with new exetended dosing of OVM-200 Oxford Vacmedix (OVM) announced today the first patient being treated with new extended dosing of OVM-200, at the prestigious Sarah Cannon Research Institute in London. The extended dosing protocol was first suggested by the clinical investiga...
Read More
Oxford Vacmedix, OVM logo
Company News
January 23, 2025 Oxford Vacmedix Comments: 0

Oxford Vacmedix announces major milestone for lead cancer vaccine OVM-200

OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable and sterile four years post manufacture – a major milestone for OVM-200 development.   Oxford, UK – 23rd January 2025 Press Release – OVM-200 Drug Product 4 year stability Oxford Vacmedix (OVM), the UK-based biopharma company developing therapeutic cancer vaccines, announced today that OVM-200 which was manufactured on contract by Eurofins Amatsi to exacting GMP standards, has bee...
Read More
Company News January 9, 2025 Oxford Vacmedix Comments: 0

Innovate UK award to OVM for clinical development of OVM-200

Oxford Vacmedix receives an Investor Partnership award from Innovate UK for the clinical development of lead cancer vaccine OVM-200. Oxford, UK _ 9 January 2025 Press Release – Innovate UK Award 09-Jan-25 Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer, confirmed today the grant of a prestigious Investor Partnership award from Innovate UK for the clinical development of its lead cancer vaccine OVM-200. The award is made as part of the SME Round 6 p...
Read More
Company News December 13, 2024 Oxford Vacmedix Comments: 0

Oxford Vacmedix licenses OVM-200 to Dx&Vx for South Korea, India and China

Oxford Vacmedix licences cancer vaccine OVM-200 to leading shareholder Dx&Vx, for development in South Korea, China, and India. Oxford, UK – 13th December 2024 Press release – OVM-200 licenced to Dx&Vx Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer, announced today the finalisation of a licensing deal for its lead cancer vaccine OVM-200, with its largest shareholder Dx&Vx. The sub-license will grant Dx&Vx rights to develop an...
Read More
Company News June 27, 2024 Oxford Vacmedix Comments: 0

Oxford Vacmedix wins 1st prize in 2024 Talent, Innovation and Entrepreurship Competition

Oxford Vacmedix has won the 1st prize in the China Overseas Talents Competition (UK Division)   The UK section of the competition was held in London on 14th June 2024 and Oxford Vacmedix won 1st prize from a strong field of 25 competitors. The international judges were impressed by the company’s groundbreaking ROP (Recombinant Overlapping Peptide) technology and its applications to develop therapeutic vaccines to treat cancer. OVM’s lead cancer vaccine, OVM-200, is in Phase 1 cl...
Read More
Company News April 25, 2024 Oxford Vacmedix Comments: 0

Regulatory approval of novel TB diagnostic in China granted to OVM licensee CBI

Regulatory approval of novel TB diagnostic in China granted to Oxford Vacmedix licensee Changzhou Biotech First regulatory approval worldwide for any application of the Recombinant Overlapping Peptide (ROP) technology Oxford, UK – 25th April 2024 Press Release – Regulatory approval granted for novel TB diagnostic Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today that its licensee, Changzhou Biotech (CBI), has been granted regula...
Read More
Company News January 31, 2024 Oxford Vacmedix Comments: 0

Oxford Vacmedix announces major milestone in clinical development of OVM-200

OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable three years post manufacture – a major milestone for OVM’s lead cancer vaccine, OVM-200 Oxford, UK – 31st January 2024 Press Release – OVM-200 major milestone three year stabilty Oxford Vacmedix (OVM), the clinical stage company developing therapeutic cancer vaccines, announced today that OVM-200 has been tested and independently certified as stable three years after manufacture. OVM...
Read More
Company News November 28, 2023 Oxford Vacmedix Comments: 0

Licensing deal with Dx&Vx for OVM-200 in South Korea and China

Ongoing discussions at an advanced stage with leading shareholder DxVx, to license OVM-200 for South Korea and for China. Oxford, UK – 28th November 2023 Press Release – Licensing deal with Dx&Vx for OVM-200 in South Korea and China Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today ongoing licensing discussions with its largest shareholder DxVx for lead cancer vaccine OVM-200. If concluded the licensing deal will grant DxVx...
Read More
Company News October 10, 2023 Oxford Vacmedix Comments: 0

New publication highlights importance of survivin as target and potential for combination use to treat cancer

A new publication in Advanced Therapeutics comprehensively reviews the rationale and preclinical results for OVM-200 both alone and in combination. Oxford, UK – 10th October 2023 Press Release – Importance of Survivin as a target and potential for combination use to treat cancer Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of vaccines to treat cancer announced today the publication of a key research paper on its lead cancer vaccine,  OVM-200. The...
Read More
Company News May 26, 2023 Oxford Vacmedix Comments: 0

Oxford Vacmedix feature in ‘Advancing Immunology’

Oxford Vacmedix to feature in ITN Business’ programme ‘Advancing Immunology’ – exploring the use of new technology to develop vaccines to treat cancer Oxford, UK – 26th May 2023 ITN Business present Oxford Vacmedix in a new series on ‘Advancing Immunology’. The programme explores how cancer therapeutic vaccines are being trialled and could reduce the need for invasive treatments such as chemotherapy and radiotherapy for some cancers in future. Watch Oxfo...
Read More
en_GBEnglish
en_GBEnglish